Phathom Pharmaceuticals, Inc. PHAT
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Phathom Pharmaceuticals, Inc. (PHAT) is a healthcare company listed in the US with a market value of about $493M. In the twelve months to September 30, 2026 it had revenue of $275M and net income of -$83M, a net margin of -30.2%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is shareholder returns (0/5).
Key numbers: a 5-year average ROIC of -292%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 248% above the current price.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. It was profitable in 0 of the last 8 years in our data. Its share count rose by 86% over three years (dilution for shareholders). It spends 19% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $275M | $175M | $55M | $682000 | $0 | — | — | — | — |
| Net income | -$83M | -$221M | -$334M | -$202M | -$198M | -$144M | -$129M | -$255M | -$1M |
| Free cash flow | -$21M | -$167M | -$267M | -$139M | -$148M | -$149M | -$71M | -$37M | — |
| EPS (diluted) | $-1.01 | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 | $-3.88 | $-22.45 | $-0.21 |
| Net margin | -30.2% | -126.4% | -605.1% | -29558.9% | — | — | — | — | — |
| ROIC | — | — | — | -199.4% | -612.1% | -65.3% | -40.8% | -33.4% | -145.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $20.05, 231% above the current price; targets range from $7.50 to $29.00; the consensus rating is “none”; expected EPS is $-0.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Phathom Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 248% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Phathom Pharmaceuticals pay a dividend?
Not currently.
Is Phathom Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Phathom Pharmaceuticals scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.